Biological parameters for the choice of antiangiogenic therapy and efficacy monitoring

M Ziche1, C Sorriso, A Parenti

  • 1Interuniversity Center of Molecular Medicine and Applied Biophysics, Medical School, University of Firenze, Italy. ziche@ds.unifi.it

Insights

This study introduces a quantitative RT-PCR method for measuring tumor angiogenesis factors. This technique enables rapid assessment of angiogenic factors and inhibitors, even in small biopsy samples.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • A disruption in the balance of pro-angiogenic and anti-angiogenic factors can lead to pathological angiogenesis.
  • Accurate measurement of tumor angiogenesis is essential for selecting effective therapeutic strategies and evaluating anti-angiogenic treatments.

Purpose of the Study:

  • To develop and validate a quantitative real-time PCR (RT-PCR) assay for measuring the expression of specific angiogenic factors and inhibitors.
  • To establish a rapid and sensitive method for the quantitative assessment of tumor angiogenesis.

Main Methods:

  • Development of a quantitative RT-PCR assay.
  • Real-time measurement of gene expression for angiogenic factors and inhibitors.
  • Application of the technique to small tissue specimens, including biopsies.

Main Results:

  • The quantitative RT-PCR method allows for rapid and accurate measurement of angiogenic factor expression.
  • The technique is sensitive enough to quantify gene expression in limited sample sizes, such as biopsies.
  • This method provides a tool for assessing the angiogenic potential of tumors.

Conclusions:

  • Quantitative RT-PCR offers a valuable tool for the precise measurement of tumor angiogenesis.
  • This technique facilitates the assessment of angiogenic factors and inhibitors in clinical settings, aiding therapeutic decisions.
  • The ability to analyze small biopsies enhances diagnostic capabilities for angiogenesis-related pathologies.